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Challenging Assumptions About Minority Participation
in US Clinical Research
Although extensive re-
searchaddressesminorities’
low participation in clinical
research, most focuses al-





ticipation in clinical trials,
and minorities might actu-
ally be overrepresented in
phase I safety studies that
require the participation
of healthy volunteers.
It is critical to consider the
entire spectrum of clinical re-
search when discussing the
participation of disenfran-
chised groups; the literature
on minorities’ distrust, poor
access, and other barriers to
trial participation needs reex-
amination. Minority partici-
pation in clinical trials is an
important topic in public
health discussions because
this representation touches on
issuesofequalityandtheelim-
inationofdisparities,whichare
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DURING THE PAST 25 YEARS,
there have been national efforts in
the United States to increase the
representation of minorities in
clinical trials.1 Discussions about
how to enhance participation have
generated an extensive literature
that addresses the low participa-
tion of minorities, especially Afri-
can Americans. Significant schol-
arly interest exists in elucidating
why these groups have histori-
cally been underrepresented in
human participant research. Al-
though current participation rates
do not fully represent the overall
population of minorities in the
United States, progress is being
made.
Currently, African Americans
and Hispanics make up12.4% and
15.8% of the US population, re-
spectively.2 A recent report indi-
cates that minorities represent al-
most 30% of those enrolled in
clinical trials sponsored by the
National Institutes of Health (NIH)
and that African Americans now
make up approximately 15% of
those minority participants.3
There is still room for improve-
ment, however, with significant
enrollment issues continuing to
affect the representation of His-
panics in clinical trials. One report
estimated Hispanic representa-
tion in NIH studies at 7.6% of
all research participants,3 and
a report on industry-sponsored
studies found that only 3% of
those participants were Hispanic.4
Increasing the participation of all
minorities in clinical trials is critical
for the production of knowledge
about new therapies because hav-
ing diverse research participants
can improve the generalizability of
medicine. Additionally, minority
participation in clinical trials is an
important topic in public health
discussions because this repre-
sentation touches on issues of
equality and the elimination of
disparities, which are core values
of the field.
Despite academic interest in the
topic, most of the focus has been
on the benefits that minority
groups can experience from clini-
cal trial participation. There has
been little discussion about the
involvement of minorities in
higher risk or lower benefit re-
search. Currently, there are no
databases aggregating demo-
graphic data from all clinical
trials––neither those sponsored
by NIH nor those sponsored by
the pharmaceutical industry.
Examining the entire spectrum
of clinical research is important
because the goals of clinical tri-
als––as well as the benefits and
risks––differ according to a
novel therapy’s stage of devel-
opment.
Clinical trials generally proceed
in 3 phases. Phase I studies are
safety studies, used to establish
appropriate doses for subsequent
clinical testing and to generate
data on adverse events. These
studies are primarily conducted by
using healthy volunteers who de-
rive no direct health benefits from
their participation. Phase II studies
are designed to provide prelimi-
nary information about the effi-
cacy of a new treatment as well as
further information about its
safety, using a few hundred par-
ticipants with the targeted disease.
Participants may derive health
benefits from phase II studies, but
only about one half of investiga-
tional therapies are shown to have
promise in phase II trials.5 Phase
III clinical trials require several
thousand volunteers with the tar-
geted disease, usually involve the
randomization of participants into
experimental and placebo arms of
the study, and can take from 2 to
4 years to complete. These studies
measure the efficacy of an in-
vestigational treatment and
sometimes a comparative bene-
fit. With an 80% success rate,
these trials are believed to offer
important health benefits to
participants.5
Despite the critical differences
between study phases––especially
between the goals of and types of
participants in phase I and phase
III studies––discussions about the
representation of minorities in
clinical trials virtually ignore these
distinctions. Most of the literature
focuses exclusively on phase III
therapeutic trials. As a result, the
existing literature may mask im-
portant issues concerning minori-
ties’ participation in clinical trials.
We propose that the representa-
tion of minorities in clinical trials
changes dramatically when taking
a broader view of study participa-
tion. Phase I safety studies elicit
a different set of findings regard-
ing the representation of minori-
ties in nontherapeutic clinical tri-
als. Most notably, data provided to
the authors by industry as part of
a larger empirical project suggest
that minorities might actually be
overrepresented in studies involv-
ing healthy volunteers (Table 1).
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Because there is currently no
comprehensive source of data
about industry clinical trials or
early phase trials at NIH, we used
the phase I participation data pro-
vided by representative sources in
industry to question the assump-
tions commonly held about mi-
norities’ participation in clinical
trials. The literature on distrust,
poor access, and other barriers to
participation needs to be reex-
amined. We argue that it is critical
to consider the entire spectrum of
clinical research when discussing




abuses in medical research have
been cited as reasons for low mi-
nority participation in contempo-
rary clinical trials. The Tuskegee
Syphilis Study, for example, has
become infamous as a grievous
example of American medical re-
search gone awry. The Tuskegee
Syphilis Study was undertaken
in 1932 to study the effects of
untreated syphilis in 399 African
American men from rural Ala-
bama, and the study continued
until 1972 although effective
treatment of syphilis became
available in the 1940s.6 This un-
ethical experiment has drawn the
ire of the research community
since it was halted, but there is no
consensus about the lasting effect
the Tuskegee Syphilis Study has
had on the general population,
particularly in reference to clini-
cal trial participation. Critics often
cite this particular study as the
primary reason that African
Americans are underrepresented
in clinical trials even today; yet,
evidence from empirical studies
investigating this point is
mixed.7,8
The Tuskegee Syphilis Study
and other examples of unethical
clinical research prompted new
federal regulations, including the
creation of institutional review
boards, which are intended to
govern the ethical conduct of re-
search.9 Underpinning US regula-
tions is the Belmont Report
(1979), written by the National
Commission for the Protection of
Human Subjects of Biomedical
and Behavioral Research in an
effort to highlight the principles
needed to guide the ethical con-
duct of human participant re-
search and to protect against trag-
edies like the Tuskegee Syphilis
Study. One of the ethical principles
outlined in the Belmont Report is
that of justice, which is concerned
with the fair distribution of the
benefits and burdens of medical
research.
Yet, even with the federal pro-
tections of research participants
implemented in the years after
publication of the Belmont Report
in 1979, minority participation in
clinical research has remained low.
These low enrollment numbers
prompted new legislative initia-
tives, such as the NIH Revitali-
zation Act of 1993, which has
a section titled ‘‘Inclusion of
Women and Minorities’’ specifi-
cally designed to ensure that
women and people of color are
given appropriate opportunities





In response to the changes in
the NIH guidelines, research has
emerged debating the merits
of minority representation in
clinical trials and the barriers
to the participation of these
groups.7,8,10---22 Common barriers
include distrust, provider percep-
tions, and access to care.
Distrust
A substantial group of scholars
has proposed that minorities,
particularly African Americans,
are distrustful of medical research
because of a history of exploita-
tion.10,12,18 Corbie-Smith et al.
interviewed African Americans to
delineate their feelings about
clinical trials participation.10 They
found that interviewees were
afraid that physicians would not
be honest with them about the
risks associated with a study, and
many were afraid of being a
guinea pig. In a 2002 follow-up
study, Corbie-Smith et al. found
that African Americans were
more likely than were Whites to
believe that physicians would not
fully explain the details of re-
search participation.7 The study
also identified African Americans’
stronger fears that their physi-
cians would allow them to par-
ticipate in a study even if serious
harm was anticipated, and 1 out
of 4 African Americans expressed
a high level of distrust in physi-
cians.7 In a more recent study
investigating minority participa-
tion in clinical research, Paskett
et al. concluded that minority pop-
ulations commonly cite mistrust
of medical research to explain
their lack of interest in clinical
trials participation.17 Likewise,
Freedman interviewed African
TABLE 1—Demographics of Phase I Participants at 1 Northeastern and 1 Southwestern
US Facility: Minority Participation in Clinical Research, June 2010
Phase I Facilities
Demographic Factor Northeast Southwest Total
Total participants 13 612 16 747 30 359
Gender, no. (%)
Men 9241 (67.9) 9306 (55.6) 18 547 (61.1)
Women 4371 (32.1) 7441 (44.4) 11 812 (38.9)
White, non-Hispanic, no. (%) 4735 (34.8) 6230 (37.2) 10 965 (36.1)
All non-White, no. (%) 8877 (65.2) 10 517 (62.8) 19 394 (63.9)
African American 5755 (42.3) 1027 (6.1) 6782 (22.3)
Asian 423 (3.1) 99 (0.6) 522 (1.7)
Hispanic 1970 (14.5) 9196 (54.9) 11 166 (36.8)
Other 729 (5.4) 195 (1.2) 924 (3.0)
Note. The data are from 2 companies’ ‘‘active’’ participant databases as queried in June 2010. The companies’ identities are confidential as
part of their participation in a broader, ongoing empirical project. We selected them on the basis of their large participant databases and the
high volume of studies they conduct for industry, which makes them representative of phase I trials conducted in the United States. Facilities
with smaller databases of participants report similar demographic data.
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American women in an effort to
capture and describe their expe-
riences with research and clinical
trials and, more generally, the
medical establishment.23 One
woman in the study noted,
We have always had a concern
about what white people have
done to black people.23(p945)
This comment implies that this
proposed mistrust extends far be-
yond medical research to include
the effect of slavery and other
historical exploitations.24
Provider Perceptions
There is also literature that
suggests that physician bias, false
perceptions, and prejudices sur-
rounding medical decision-making
dictate the lower number of mi-
nority participants in trials. Re-
search has shown that physicians
are less likely to prescribe certain
treatments to their minority pa-
tients. As an example, Smedley
et al. speculated that physicians
operate on a cognitive heuristic
learned in medical school and
residency that brings prior expec-
tations to each individual encoun-
ter with their patients.19 The phy-
sicians’ prior experiences treating
persons of similar race, gender,
age, and socioeconomic status as
themselves enter into their deci-
sion-making process. Smedley et
al. concluded that physicians’
biases do affect actual treatment
decisions, although they claim that
this does not mean there is a lesser
quality of care for minority pa-
tients.19 Nonetheless, a landmark
study by Schulman et al. identified
the effect of race and gender on
patient referral for cardiac cathe-
terization.25 Findings showed that
African American women were
least likely to be referred for this
important procedure.25 Moreover,
van Ryn and Burke found that
physicians are more likely to have
negative impressions of their Afri-
can American patients than of
their White patients and are likely
to believe that African American
patients are less intelligent and
educated than are their White
patients.26
Perhaps most significant in re-
lation to a discussion of clinical trial
participation, van Ryn and Burke
also found that physicians are bi-
ased concerning who they believe
will comply with difficult therapeu-
tic regimens.26 Their study suggests
that physicians believe African
Americans are two thirds as likely
to be adherent as are their White
patients. Of course, participation in
clinical trials research can be a rig-
orous and demanding enterprise.
Thus, it holds that one possible
explanation for the underrepresen-
tation of minorities is that physi-
cians do not believe that their Afri-
can American patients will adhere
to the prescribed protocol.
Access to Care
An additional argument that
warrants acknowledgment is that
people of color have historically
had poor access to medical care. In
fact, some studies indicate that the
majority of disenfranchised mi-
norities have access only to pro-
viders and hospitals that have
limited resources.27---30 Minorities
are less likely than are Whites to
have health insurance, a prerequi-
site for gaining access to many
medical facilities and for some
phase III clinical trials.21,31 As
a consequence, many minorities
receive care only in an emergency
room setting, where they are seen
by a variety of physicians who are
likely unfamiliar with them and
unconcerned with enrolling them
in a clinical trial.18,32
Willingness to Participate
Despite these factors, research
demonstrates that minorities are,
in fact, willing to participate in
clinical trials. Wendler et al.
found that minorities are as will-
ing to participate as are Whites
but that they are not asked to
participate.22 A more recent se-
ries of studies by Katz et al. pro-
vides evidence that knowledge of
the Tuskegee study does not in-
fluence minorities’ participation
rates and that, again, people of
color are willing to participate in
medical research despite percep-
tions that they are not.13---16 There
is a paucity of literature compar-
ing the views of minorities with
those of Whites, and the few
studies that have been conducted
imply that minorities’ perceptions
of clinical trials are similar to
those of Whites. For instance,
Brown and Topcu found that
African Americans were more
likely to know about Tuskegee
than were Whites but were not
significantly less likely to be will-
ing to participate in a clinical trial
compared with Whites.8 Brandon
et al.33 and Katz et al.16 also found
that African Americans are not
less likely than are Whites to
participate in clinical trials when
asked to do so, regardless of prior
knowledge of Tuskegee. Brandon
et al. did, however, argue that
African Americans were more
distrusting of medical care in
general but concluded that this





Issues of trust, physician per-
ceptions and biases, and structural
issues such as access to health care
might factor into the low levels of
minority participation in thera-
peutic clinical trials. However, the
literature on minority participa-
tion focuses almost exclusively on
phase III research. Thus, current
investigations ignore the partici-
pation of minorities as healthy
volunteers in important safety
testing performed during phase I
work. Although it has been an
underreported phenomenon with
few high-quality publications on
the topic, we propose that minor-
ities might be overrepresented in
phase I trials, which has different
implications for research.
Participation Rates
It is currently difficult to assess
precisely the demographics of
phase I participants because of
the lack of centralized databases
containing this type of informa-
tion across clinical trials. More-
over, few studies report aggregate
information about phase I trial
participants, and those that do
tend to focus on the underrepre-
sentation of women in these early
phase studies.34---36 However,
those who work in the industry
claim that a high percentage of
African Americans participate at
phase I facilities in the northeast-
ern United States and that a high
percentage of Hispanics partici-
pate in the southwestern United
States, meaning that these groups
are represented in percentages
much greater than their represen-
tation in the US population.37--39
In 2009, the representation of
African Americans and Hispanics
in the US population was 12.4%
and 15.8%, respectively.2 Yet, an-
ecdotal evidence within the indus-
try has put both of these groups at
rates closer to 40% of participants
each in phase I trials.37
As part of a larger empirical
project on phase I clinical trials in
the United States, we obtained
demographic data on healthy vol-
unteers from 2 of the largest phase
I facilities in the country (out of
approximately 40 such clinics):
1 in the Northeast and 1 in the
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Southwest. These preliminary
data evince this demographic pat-
tern of high ethnic and racial
minority enrollment (Table 1). In
both facilities, the percentage of
minority participants is much
greater than that of White volun-
teers (63.9% compared with
36.1%, respectively). African
Americans make up 42.3% of the
healthy volunteers in the North-
east and 6.1% in the Southwest,
for an average of 22.3% between
the 2 facilities. This figure repre-
sents nearly double the proportion
of African Americans one would
expect on the basis of population
alone. Hispanics make up 14.5%
of the healthy volunteers in the
Northeast and 54.9% in the
Southwest, for an average of
36.8% between the 2 facilities.
This finding means that Hispanics
are represented at more than twice
the rate expected on the basis of US
population statistics and almost 5
times their representation in NIH-
sponsored phase III studies. We
acknowledge that these data are not
definitive; nonetheless, they illus-
trate that minority participation in
phase I trials is higher than expected
on the basis of US demographic data
and their representation in thera-
peutic trials.
Revisiting the Barriers to
Participation
The higher than expected par-
ticipation of minorities as healthy
volunteers in phase I studies in-
dicates that it is necessary to re-
visit and reevaluate the proposed
barriers to their participation.
Specifically, examining phase I
trials puts in doubt the argument
about minorities’ distrust of
medical research. If minorities,
especially African Americans,
were as distrustful of medical re-
search as the literature suggests, it
would not follow that this sup-
posedly underrepresented group
would enroll in such high num-
bers in phase I studies. It would
be a paradox for minorities to
participate in the riskiest studies
and not participate in the studies
that could most benefit their
medical conditions.
Although the argument that
physician bias may contribute to
the underrepresentation of mi-
norities in phase III trials is not
challenged by the phase I data,
there is evidence of an interesting
complementary phenomenon that
could be occurring. One study
found that a phase I facility in the
Southwest perceived Hispanic
volunteers as more adherent than
other groups, and they invested
additional resources in hiring
Spanish-speaking staff, translating
consent forms into Spanish, and
recruiting in the Hispanic com-
munity to target that group.37
Moreover, arguments concerning
physicians’ biases and stereotypes
also carry little weight in discus-
sions of phase I trials because of
the limited involvement of physi-
cian investigators in recruitment.
Private sector contract research
organizations and pharmaceutical
companies’ clinical pharmacology
units hire large numbers of re-
cruiters and other research staff
who recruit, organize, and run
most phase I studies. In addition,
phase I clinics tend to be located in
economically depressed areas of
the United States, with a higher
concentration of clinics located in
the Northeast and in urban
areas.37 These locations tend to





trust, provider perceptions, and
access become more complex
when comparing the recruitment
of patients for testing the efficacy
of a product (phase III) versus the
recruitment of healthy volunteers
for testing the safety of a product
(phase I). A crucial difference be-
tween these types of research
studies is that volunteers are usu-
ally paid large sums for their par-
ticipation in phase I trials.39,40
Hence, arguments about altruistic
notions that may be relevant to
phase III research are much less
applicable to phase I volunteers’
motivations. This becomes partic-
ularly pertinent when considering
that many phase I participants
use trials as a major source of
income. In fact, there are people
who have made a career of par-
ticipating in phase I clinical tri-
als.41 Critics have commented
that the financial remuneration
has led to the creation of a pro-
fession, that of the guinea
pig.42,43 Whereas phase III trial
participants have cited fear of
being a guinea pig,10 phase I
participants have welcomed this
terminology.44,45 Because of the
loaded nature of the term, how-
ever, the US Food and Drug
Administration, pharmaceutical
companies, and contract research
organizations have chosen to re-
fer to these professional volun-




The ethical issues associated
with phase I trials are also differ-
ent from those of later phase
studies given that healthy volun-
teers do not experience any health
benefits from their participation
but do bear a considerable burden
of risk.47 Serving as reminders of
the potential dangers associated
with phase I testing are the deaths
of healthy volunteers at Johns
Hopkins and Lilly in 2001 and
2004, respectively, and the near
fatal TeGenero phase I study in
London in 2006 of a humanized
monoclonal antibody that caused
multiple organ failure in 6 healthy
volunteers.48 Although there is
some literature examining the
ethics of phase I trials,46,49---52
current discussions and ethical
debates tend to focus on the re-
cruitment of impoverished people,
but they often ignore the implica-
tions of disenfranchised minorities
turning to phase I clinical trials for
a primary source of income. The
fact remains that we cannot la-
ment, on one hand, the legacy of
Tuskegee and the distrust that it
might have caused while ignoring,
on the other, that minorities as
a group might again be assuming
much of the risk of biomedical
research without sharing the ben-
efit (through either participation in
later phase trials or access to
pharmaceuticals once they are
made available on the market).
This would be a violation of the
ethical principle of justice outlined
in the Belmont Report and may
render ineffectual the federal
safeguards employed to protect
research participants.9
CONCLUSIONS
Research that promotes a more
accurate understanding of minor-
ity participation in clinical trials
has significant public health im-
plications because it relates to
efforts to eliminate disparities and
achieve equality through clinical
research. Currently, there seems
to be an unequivocal belief that
participation in clinical studies is
both necessary and beneficial for
minority populations. We assert
that this is an overly simplistic
view. Instead, the participation of
minorities in clinical trials should
be framed in 2 ways. First, indi-
viduals of diverse ethnic and racial
backgrounds should have the
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opportunity to participate in clini-
cal trials. This is important from
the perspective of fairness, and
diversifying participants in clinical
trials leads to better science and
creates the potential to reduce
health disparities in medicine.
Second, medical research must not
unduly burden or exploit particu-
lar groups in society. Regardless of
the reasons for the overrepresen-
tation of minorities in phase I trials
and the continued underrepre-
sentation of minorities in phase III
trials, we need to consider these
phenomena from an ethical
standpoint. Minorities share a dis-
proportionately greater risk and
enjoy disproportionately fewer
benefits (from a health and disease
standpoint) from participating in
clinical trials. If we as a research
community are genuinely con-
cerned about the legacies of
exploiting minorities for the sake of
medical progress, we should ques-
tion the current system of phase I
testing that could lead marginalized
communities to believe even more
that the research community treats
their members as human guinea
pigs that fill a particular need in the
global economy.53,54 j
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Eye Disease Resulting From Increased Use of Fluorescent
Lighting as a Climate Change Mitigation Strategy
Increased use of fluores-
cent lighting as a climate
change mitigation strategy
may increase eye disease.
The safe range of light to
avoid exposing the eye to
potentially damaging ultra-
violet (UV) radiation is 2000
to 3500K and greater than
500 nanometers. Some fluo-
rescent lights fall outside
this safe range.
Fluorescent lighting may
increase UV-related eye dis-
eases by up to 12% and, ac-
cording to our calculations,
maycauseanadditional3000
cases of cataracts and 7500
cases of pterygia annually in
Australia.
Greater control of UV ex-
posure from fluorescent
lights is required. This may
be of particular concern for
aging populations in deve-
loped countries and coun-
tries in northern latitudes
where there is a greater de-
pendence on artificial light-
ing. (Am J Public Health.
2011;101:2222–2225. doi:
10.2105/AJPH.2011.300246)
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CLIMATE CHANGE MITIGATION
will involve numerous changes in
the use of technology. Many peo-
ple worldwide are exposed to ar-
tificial light sources both in the
home and in the workplace. Until
recently, this mainly entailed ex-
posure to incandescent lights and,
less frequently, to fluorescent
lighting. Moves to sustainability
and a low-carbon economy have
involved the phasing out of in-
candescent lights and a shift to-
ward more energy-efficient light-
ing in a number of countries,
including Australia and the coun-
tries of the European Union.1,2 In
the United States, federal law
stipulates that incandescent lights
be phased out by 2014.3
Globally, increasing numbers of
workers spend their work time in
buildings rather than in fields or
other outside locations and are thus,
regularly and for extended pe-
riods, exposed to ultraviolet (UV)
radiation via fluorescent lighting.
This increase is partly due to rapid
urbanization and the increasingly
knowledge-based society (attract-
ing workers into offices) in which
we live. Although fluorescent
lighting has been used in schools
and offices for many years, only in
recent years has it dominated UV
exposure in the home, and it will
continue to do so in future years.
The types of energy-efficient
lighting with which incandescent
lights are being replaced are high-
intensity discharge (HID) lamps,
light-emitting diodes (LEDs), and
fluorescent lighting, including the
popular compact fluorescent
lamps (CFLs). All of these light
sources are more efficient than the
incandescent lamp, which electri-
cally heats a tungsten filament so
that it glows but loses much en-
ergy as heat.4 CFLs, for example,
use 75% less energy than do in-
candescent lamps.5
HID lamps produce intense
light in a small area, and although
they are less energy efficient than
fluorescent lights, they are used
widely for lighting large areas such
as streets and sports facilities.6
LEDs are energy efficient but not
as bright, stable, or cheap as fluo-
rescent lights. Fluorescent lighting,
with its minimal energy demands,
is considered to provide the most
efficient form of light, one that
most closely resembles daylight
and provides the visual acuity
necessary for task performance.
Consequently, as a result of the
popularity of fluorescent lighting
a large number of people are now
exposed to artificial sources of UV
radiation emitted from these
lights. Could this be a precursor to
a substantial increase in future
eye disease? We examine the po-




A fluorescent lamp or tube is
a gas-discharge device that uses
electricity to excite mercury vapor.
The excited mercury atoms pro-
duce UV radiation, which causes
the phosphorescent coating inside
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